皓元医药(688131.SH)上半年净利润1.52亿元，同比增长115.55%

Core Viewpoint - Haoyuan Pharmaceutical (688131.SH) reported a significant increase in revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential [1] Financial Performance - The company achieved a total operating revenue of 1.311 billion yuan, representing a year-on-year growth of 24.2% [1] - The net profit attributable to shareholders reached 152 million yuan, showing a remarkable year-on-year increase of 115.55% [1] - Basic earnings per share were reported at 0.72 yuan [1] Dividend Distribution - The company proposed a cash dividend of 0.8 yuan per 10 shares (tax included) for all shareholders [1]